An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Bosutinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults.

Trial Profile

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Bosutinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2009

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Breast cancer; Chronic myeloid leukaemia; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 17 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Actual initiation date (1 Oct 2008) and trial location (Poland) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top